131 related articles for article (PubMed ID: 38574396)
1. Non-invasive prediction nomogram for predicting significant fibrosis in patients with metabolic-associated fatty liver disease: a cross-sectional study.
Zhang F; Han Y; Mao Y; Zheng G; Liu L; Li W
Ann Med; 2024 Dec; 56(1):2337739. PubMed ID: 38574396
[TBL] [Abstract][Full Text] [Related]
2. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a nomogram model for predicting the risk of MAFLD in the young population.
Yuan Y; Xu M; Zhang X; Tang X; Zhang Y; Yang X; Xia G
Sci Rep; 2024 Apr; 14(1):9376. PubMed ID: 38654043
[TBL] [Abstract][Full Text] [Related]
4. Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis.
Huang CF; Liang PC; Wang CW; Jang TY; Hsu PY; Tsai PC; Wei YJ; Yeh ML; Hsieh MY; Lin YH; Huang CK; Dai CY; Huang JF; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2024 Apr; 40(4):374-383. PubMed ID: 38234005
[TBL] [Abstract][Full Text] [Related]
5. Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram.
Zhou YJ; Ye FZ; Li YY; Pan XY; Chen YX; Wu XX; Xiong JJ; Liu WY; Xu SH; Chen YP; Zheng MH
United European Gastroenterol J; 2019 Oct; 7(8):1124-1134. PubMed ID: 31662869
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a nomogram for predicting metabolic-associated fatty liver disease in the Chinese physical examination population.
Zhou B; Gong N; Huang X; Zhu J; Qin C; He Q
Lipids Health Dis; 2023 Jun; 22(1):85. PubMed ID: 37386566
[TBL] [Abstract][Full Text] [Related]
7. Validation of Non-invasive Fibrosis Scores for Predicting Advanced Fibrosis in Metabolic-associated Fatty Liver Disease.
Chen X; Goh GB; Huang J; Wu Y; Wang M; Kumar R; Lin S; Zhu Y
J Clin Transl Hepatol; 2022 Aug; 10(4):589-594. PubMed ID: 36062270
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a new nomogram to screen for MAFLD.
Zou H; Zhao F; Lv X; Ma X; Xie Y
Lipids Health Dis; 2022 Dec; 21(1):133. PubMed ID: 36482400
[TBL] [Abstract][Full Text] [Related]
9. Nomogram for predicting advanced liver fibrosis and cirrhosis in patients with chronic liver disease.
Ding R; Zhou X; Huang D; Wang Y; Li X; Yan L; Lu W; Yang Z; Zhang Z
BMC Gastroenterol; 2021 Apr; 21(1):190. PubMed ID: 33906623
[TBL] [Abstract][Full Text] [Related]
10. MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease.
Cheung JTK; Zhang X; Wong GL; Yip TC; Lin H; Li G; Leung HH; Lai JC; Mahadeva S; Nik Mustapha NR; Wang XD; Liu WY; Wong VW; Chan WK; Zheng MH
Aliment Pharmacol Ther; 2023 Dec; 58(11-12):1194-1204. PubMed ID: 37724633
[TBL] [Abstract][Full Text] [Related]
11. Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes.
Lim TS; Chun HS; Kim SS; Kim JK; Lee M; Cho HJ; Kim SU; Cheong JY
Gut Liver; 2023 Jul; 17(4):610-619. PubMed ID: 36799062
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals.
Eren F; Kaya E; Yilmaz Y
Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):98-103. PubMed ID: 32976186
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the prognostic value of a comprehensive set of predictors in identifying risk of metabolic-associated fatty liver disease among employed adults.
Yang Z; Yu B; Wang Z; Li Z; Yang B; Zeng H; Yang S
BMC Public Health; 2023 Mar; 23(1):584. PubMed ID: 36991357
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
15. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
Huang C; Seah JJ; Tan CK; Kam JW; Tan J; Teo EK; Kwek A; Wong YJ; Tan M; Ang TL; Kumar R
Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101528. PubMed ID: 33268036
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
Younes R; Caviglia GP; Govaere O; Rosso C; Armandi A; Sanavia T; Pennisi G; Liguori A; Francione P; Gallego-Durán R; Ampuero J; Garcia Blanco MJ; Aller R; Tiniakos D; Burt A; David E; Vecchio FM; Maggioni M; Cabibi D; Pareja MJ; Zaki MYW; Grieco A; Fracanzani AL; Valenti L; Miele L; Fariselli P; Petta S; Romero-Gomez M; Anstee QM; Bugianesi E
J Hepatol; 2021 Oct; 75(4):786-794. PubMed ID: 34090928
[TBL] [Abstract][Full Text] [Related]
17. Red blood cell distribution width derivatives in alcohol-related liver cirrhosis and metabolic-associated fatty liver disease.
Michalak A; Guz M; Kozicka J; Cybulski M; Jeleniewicz W; Lach T; Cichoż-Lach H
World J Gastroenterol; 2022 Oct; 28(38):5636-5647. PubMed ID: 36304090
[TBL] [Abstract][Full Text] [Related]
18. Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort.
Tang LJ; Sun DQ; Song SJ; Yip TC; Wong GL; Zhu PW; Chen SD; Karsdal M; Leeming DJ; Jiang P; Wang C; Chen Q; Byrne CD; Targher G; Eslam M; George J; Wong VW; Zheng MH
Liver Int; 2024 May; 44(5):1129-1141. PubMed ID: 38426611
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
[TBL] [Abstract][Full Text] [Related]
20. Sex- and region-specific associations of skeletal muscle mass with metabolic dysfunction-associated fatty liver disease.
Xiao P; Liang P; Gao P; Wu J
Front Endocrinol (Lausanne); 2022; 13():1057261. PubMed ID: 36531457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
